VC005 tablets: VC005 repeat administration for up to 24 weeks
Study summary
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
Eligibility
Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
* The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF).
* Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 30 kg.
* Subjects with a clinical diagnosis of non-segmental vitiligo
Exclusion Criteria:
* Pregnant or breastfeeding women, or subjects planning to become pregnant or breastfeed during the study period.
* Trial participants with complete depigmentation of hair within the vitiligo area.
* Trial participants clinically diagnosed with segmental vitiligo, mucosal non-segmental vitiligo, or other cutaneous depigmentation disorders.
Primary outcome measure(s)
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC） — Day1，Day28
Peak Plasma Concentration (Cmax） — Day1，Day28
Trial sites (1)
Facility
City
Region
Status
The Peking University People's Hospital
Beijing
Beijing Municipality
More Jiangsu vcare pharmaceutical technology co., LTD trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.